

E. Salzsieder¹, L. Vogt¹, KD. Kohnert¹, P. Heinke¹, A. Abdulazim², Z. Metwali², O. Attef², I. Salman², P. Augstein¹

CGMS™ in combination with KADIS® has a high potential to improve out-patient diabetes care

¹Institute of Diabetes "Gerhardt Katsch" Karlsburg, Germany

²Ajman University of Science and Technology Network, Ajman, UAE

The World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy)
October 26-29 2006, Berlin, Germany



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein

Background



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsruhe
©Salzsieder/Augstein

Proof of concept, technology and acceptance for:

- ✓ **CGMS™**, continuous 72-hour glucose monitoring
- ✓ **KADIS®**, a patient-centred advisory system applicable as decision support for GP's with diabetic patients
- ✓ **TeleDIAB®**, a telemedicine-based communication system for Integrated Diabetes Care



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein

Research Design and Methods



DIROC Ltd.
Diabetes Research and Outpatient Center




DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein

I. Design:




- Multi-centric case/control study with 5 outpatient centres
- Insulin-treated diabetics (n=62), Age 17-75 years,
- Randomization for **CGMS™-** or **CGMS™+ KADIS®-**based decision support



II. Methods:


(1) Continuous 72h-blood glucose monitoring



(2) Characteristic blood glucose profile CTP, the „Metabolic Finger-Print“ estimation and weak point analysis



(3) KADIS[®] - Report






(4) Application of KADIS[®]-based recommendations

at baseline




3 months later



III. Statistics:

Verification of the **outcome**: HbA1c (%), MBG (mmol/L) and hyperglycemia (h/day)] by **matching** for HbA1c and MBG at baseline



IV. Patient demographics

Parameter	CGMS™	CGMS™/KADIS®
N	31	31
Sex (f/m)	15/16	14/17
Age (y)	47.5 ± 2.4	45.5 ± 2.5
Diabetes duration (y)	12.2 ± 1.9	13.7 ± 1.6
BMI (kg/m ²)	30.1 ± 1.4	31.5 ± 1.1
Diabetes type (1/2)	19/12	14/17
Insulin (IU)	59.0 (37–76)	53.0 (34–80)
Diabetes specialist/ General practitioner	26/5	18/13



RESULTS



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein


Type 1 Diabetes

Before & After Application of CGMS™/ KADIS®-based Recommendations


P-52675667

Gender: f

Age: 20 years



1st CGMS™/KADIS® Trial



2nd CGMS™/KADIS® Trial

Two CGMS™ Trials, 3 months apart in a type 1 diabetic volunteer before and after application of KADIS®-based recommendations




Type 2 Diabetes

Before & After Application of CGMS™/KADIS®-based Recommendations


P-19749724

Gender: m

Age: 49 years



1st CGMS™/KADIS® Trial




2nd CGMS™/KADIS® Trial

Two CGMS™ Trials 3 months apart in a type 2 diabetic volunteer before and after application of KADIS®-based recommendations



Outcome: HbA1c




Change in HbA1c within 3 months				
CGMS™	6.0 → 6.5	7.2 → 7.6	8.6 → 8.5	7.9 → 8.0
CGMS™/KADIS®	6.1 → 6.1	7.2 → 6.9	8.5 → 7.7	8.0 → 7.4
net KADIS® effect	0.5 ± 0.3	0.7 ± 0.1**	0.6 ± 0.2**	0.7 ± 0.2**

*p< 0.05; ** p< 0.01



Outcome: Mean Blood Glucose (MBG)




Change in MBG within 3 months				
CGMS™	6.0 → 7.3	8.4 → 8.6	9.1 → 9.4	8.6 → 8.9
CGMS™/KADIS®	6.7 → 7.3	8.0 → 7.3	9.2 → 7.7	8.7 → 7.6
net KADIS® effect	0.1 ± 1.7	0.8 ± 0.7	1.7 ± 0.6**	1.4 ± 0.5**

*p< 0.05; ** p< 0.01



Outcome: Hyperglycaemic Episodes (h/day)



Change in duration of hyperglycemia within 3 months				
CGMS™	0.6 → 1.6	5.5 → 6.1	7.7 → 8.2	6.2 → 6.8
CGMS™/KADIS®	0.7 → 0.0	4.4 → 3.3	8.7 → 4.3	6.9 → 3.7
net KADIS® effect	1.7 ± 0.9	1.7 ± 2.3	4.8 ± 2.0*	3.8 ± 1.4*

*p < 0.05; ** p < 0.01



Conclusion



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein

- ✓ Applicability of the combined KADIS[®]/CGMS[™] approach
- ✓ Implication as powerful tool for out-patient diabetes care
- ✓ Proof of concept, technology and acceptance for a

Integrated Diabetes Health Care Network

providing KADIS[®]/CGMS[™]/TeleDIAB[®]
for out-patient diabetes care



DIROC Ltd.
Diabetes Research and Outpatient Center




DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsruhe
©Salzsieder/Augstein

Integrated Diabetes Health Care Network

Physician/
Patient:
Application
of CTP and
KADIS® -
Report



CGMS™
Monitoring:
Patient at
home

DCC®: Generates the patient specific
CTP („Metabolic Finger-Print“) and
provides recommendations to optimize
metabolic control
(The KADIS®-Report)



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
Karlsruhe



Institut für Diabetes
"Gerhardt Katsch" Karlsruhe
©Salzsieder/Augstein

Further Activities



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsburg
©Salzsieder/Augstein

Establishing the **Integrated Diabetes Health Care Network (IDN)**

Services, which will be provided by the IDN:

- (1) Continuous 72h-glucose monitoring under daily life conditions
- (2) Estimation of the patient specific CTP (“Metabolic Finger-Print”) including “Weak Point” analysis
- (3) Generation of evidence-based recommendations to overcome the identified weak points (KADIS[®]-Report)
- (4) Application of KADIS[®]-based recommendations

The generous support of this study by grants of the German Ministry for Education and Research (BMBF) and Medtronic MiniMed Inc., Northridge, USA, is highly appreciated



DIROC Ltd.
Diabetes Research and Outpatient Center



DCC
Diabetes Service Center
K a r l s b u r g



Institut für Diabetes
"Gerhardt Katsch" Karlsruhe
©Salzsieder/Augstein